Hugh Salter
Chief Scientific Officer Anocca AB
Seminars
Wednesday 17th September 2025
Spearheading the Development of TCR-Based Approaches for Inhibition of RAS-Driven Cancers in Resistant Patient Populations
3:15 pm
- Identifying and quantifying precise HLA-peptide targets for TCR-based therapies
- Novel specificity analysis of TCR to avoid off-target toxicities
- Focused clinical trial designs to integrate with existing standard of care for RAS-driven malignancies
Thursday 18th September 2025
Panel Discussion: Delving into Strategies to Achieve Selective Targeting of NRAS & HRAS Mutations for Successfully Treating a Wide Array of Cancers
2:30 pm
- What preclinical evidence is there which showcases the potential for NRAS-targeting programs?
- How to selectively target NRAS and minimize off-target effects?
- How to develop a successful patient stratification strategy and clinical trial design for RAS-mutant cancer programs?
